http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 08:12:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+28/26993257.html si-local-file:///var/storage/secattach/20260828/26993257.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+28/26993257.html Fri, 28 Aug 2026 08:12:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+28/26993257.html si-local-file:///var/storage/secattach/20260828/26993257.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+28/26993257.html Fri, 28 Aug 2026 08:12:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+28/26993257.html si-local-file:///var/storage/secattach/20260828/26993257.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+28/26993257.html Fri, 28 Aug 2026 08:12:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/Equity+Offerings/BioLineRx+plans+%243.75M+share+offering+at+%242.78+per+ADS/26993191.html <p>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) has entered into a definitive agreement for a registered direct offering of 1,348,921 American Depositary Shares at $2.78 per ADS, with gross proceeds expected to total $3.75 million before placement agent fees and other expenses.</p> <p>The Tel Aviv-based company has also agreed to issue warrants to purchase up to 2,023,382 ADSs at an exercise price of $2.78 per ADS through a concurrent private placement. The warrants will expire five years from the issuance date. Each ADS represents 600 ordinary shares with a par value of NIS 0.10 per share.</p> <p>The offering is expected to close on http://www.streetinsider.com/Equity+Offerings/BioLineRx+plans+%243.75M+share+offering+at+%242.78+per+ADS/26993191.html Fri, 28 Aug 2026 08:00:21 -0400 BLRX O.05892620 http://www.streetinsider.com/Equity+Offerings/BioLineRx+plans+%243.75M+share+offering+at+%242.78+per+ADS/26993191.html <p>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) has entered into a definitive agreement for a registered direct offering of 1,348,921 American Depositary Shares at $2.78 per ADS, with gross proceeds expected to total $3.75 million before placement agent fees and other expenses.</p> <p>The Tel Aviv-based company has also agreed to issue warrants to purchase up to 2,023,382 ADSs at an exercise price of $2.78 per ADS through a concurrent private placement. The warrants will expire five years from the issuance date. Each ADS represents 600 ordinary shares with a par value of NIS 0.10 per share.</p> <p>The offering is expected to close on http://www.streetinsider.com/Equity+Offerings/BioLineRx+plans+%243.75M+share+offering+at+%242.78+per+ADS/26993191.html Fri, 28 Aug 2026 08:00:21 -0400 BLRX O.05892620 http://www.streetinsider.com/Press+Releases/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX) ("<span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx</span>" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of <money>$2.78</money> per ADS (or per ADS equivalent) through a registered direct offering. In addition, the Company has agreed to issue accompanying warrants to purchase up to http://www.streetinsider.com/Press+Releases/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html Fri, 28 Aug 2026 08:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/Press+Releases/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX) ("<span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx</span>" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of <money>$2.78</money> per ADS (or per ADS equivalent) through a registered direct offering. In addition, the Company has agreed to issue accompanying warrants to purchase up to http://www.streetinsider.com/Press+Releases/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html Fri, 28 Aug 2026 08:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/Press+Releases/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX) ("<span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx</span>" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of <money>$2.78</money> per ADS (or per ADS equivalent) through a registered direct offering. In addition, the Company has agreed to issue accompanying warrants to purchase up to http://www.streetinsider.com/Press+Releases/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html Fri, 28 Aug 2026 08:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/PRNewswire/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX) ("<span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx</span>" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of <money>$2.78</money> per ADS (or per ADS equivalent) through a registered direct offering. In addition, the Company has agreed to issue accompanying warrants to purchase up to http://www.streetinsider.com/PRNewswire/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html Fri, 28 Aug 2026 08:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/PRNewswire/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX) ("<span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx</span>" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of <money>$2.78</money> per ADS (or per ADS equivalent) through a registered direct offering. In addition, the Company has agreed to issue accompanying warrants to purchase up to http://www.streetinsider.com/PRNewswire/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html Fri, 28 Aug 2026 08:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/PRNewswire/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX) ("<span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx</span>" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of <money>$2.78</money> per ADS (or per ADS equivalent) through a registered direct offering. In addition, the Company has agreed to issue accompanying warrants to purchase up to http://www.streetinsider.com/PRNewswire/BioLineRx+Announces+%243.75+Million+Registered+Direct+Offering+and+Concurrent+Private+Placement/26993162.html Fri, 28 Aug 2026 08:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/Press+Releases/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html <div class="xn-content"> <p class="prntac"><i>Management to Hold Conference Call at <chron>8:30 a.m. EDT</chron></i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Monday, August 31, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets open.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html Tue, 25 Aug 2026 07:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/Press+Releases/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html <div class="xn-content"> <p class="prntac"><i>Management to Hold Conference Call at <chron>8:30 a.m. EDT</chron></i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Monday, August 31, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets open.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html Tue, 25 Aug 2026 07:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/Press+Releases/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html <div class="xn-content"> <p class="prntac"><i>Management to Hold Conference Call at <chron>8:30 a.m. EDT</chron></i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Monday, August 31, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets open.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html Tue, 25 Aug 2026 07:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/PRNewswire/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html <div class="xn-content"> <p class="prntac"><i>Management to Hold Conference Call at <chron>8:30 a.m. EDT</chron></i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Monday, August 31, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets open.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html Tue, 25 Aug 2026 07:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/PRNewswire/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html <div class="xn-content"> <p class="prntac"><i>Management to Hold Conference Call at <chron>8:30 a.m. EDT</chron></i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Monday, August 31, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets open.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html Tue, 25 Aug 2026 07:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/PRNewswire/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html <div class="xn-content"> <p class="prntac"><i>Management to Hold Conference Call at <chron>8:30 a.m. EDT</chron></i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended <chron>June 30, 2026</chron> on <chron>Monday, August 31, 2026</chron>, before the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets open.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/BioLineRx+to+Report+Second+Quarter+2026+Results+on+August+31%2C+2026/26970657.html Tue, 25 Aug 2026 07:00:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+18/26944129.html si-local-file:///var/storage/secattach/20260818/26944129.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+18/26944129.html Tue, 18 Aug 2026 16:04:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+18/26944129.html si-local-file:///var/storage/secattach/20260818/26944129.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+18/26944129.html Tue, 18 Aug 2026 16:04:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+18/26944129.html si-local-file:///var/storage/secattach/20260818/26944129.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Aug+18/26944129.html Tue, 18 Aug 2026 16:04:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/Corporate+News/BioLineRx+and+Hemispherian+to+present+GLIX1+ovarian+cancer+data+at+ESMO/26786873.html <p>BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS announced that an abstract featuring pre-clinical data on GLIX1 in combination with PARP inhibitors has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), scheduled for October 23–27 in Madrid, Spain.</p><p>The presentation, titled "GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell Lines," will appear in the e-Poster Area, Hall 25, under presentation number 1435eP. The data focuses on pre-clinical findings in HR-proficient ovarian cancer cell lines.</p><p>GLIX1 is an orally administered small molecule that activates the TET2 http://www.streetinsider.com/Corporate+News/BioLineRx+and+Hemispherian+to+present+GLIX1+ovarian+cancer+data+at+ESMO/26786873.html Mon, 20 Jul 2026 07:02:36 -0400 BLRX http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986